Each year on World Brain Day, the World Federation of Neurology (WFN) shines a global spotlight on the importance of brain health and the burden of neurological disorders. In 2025, this important observance carries the theme “Brain Health for All Ages”, encouraging conversations around innovation, research, and equitable care in neurology.
At Plus Therapeutics, we are proud to be at the forefront of clinical research aimed at transforming the treatment landscape for glioblastoma (GBM)—one of the most aggressive and devastating forms of brain cancer.
Innovations in GBM Research: A Conversation with Dr. Andrew Brenner
In recognition of World Brain Day, we’re highlighting a recent Cancer Network interview with Andrew Brenner, M.D., Ph.D., a Principal Investigator for our ReSPECT-GBM clinical trial. In the video, Dr. Brenner discusses how immunotherapy and therapeutic vaccines are showing potential as breakthrough treatments in glioblastoma.
Dr. Brenner also reviews promising data from our Phase 1/2 ReSPECT-GBM trial (NCT01906385), which evaluated rhenium (Re186) obisbemeda, our lead radiotherapeutic candidate, in patients with recurrent glioma. The results showed meaningful efficacy and safety, providing hope for those facing this difficult disease.
Watch the full video interview here:
Cancer Network Interview with Dr. Brenner
Clinical Trial Enrollment Is Ongoing
Our team is actively enrolling patients in the Phase 2 ReSPECT-GBM trial. This trial is designed to further evaluate REYOBIQ™ (rhenium Re186 obisbemeda), a targeted radiotherapeutic delivered directly into the tumor cavity, with the goal of achieving precise, localized treatment while minimizing systemic side effects.
If you or someone you know may be eligible, please visit our ReSPECT-GBM clinical trial page or contact us directly at respect@plustherapeutics.com.
Why Brain Health Awareness Matters
Raising awareness of neurological disorders—including malignant brain tumors like GBM—is crucial to driving innovation and accelerating access to better treatments. On this World Brain Day, we reaffirm our commitment to advancing science and improving outcomes for patients with some of the most urgent unmet needs in oncology.
Learn more about Plus Therapeutics and our mission:
plustherapeutics.com
#WorldBrainDay #BrainHealth #Glioblastoma #GBM #BrainTumorAwareness #NeuroOncology #ClinicalTrials #CancerResearch #REYOBIQ #ReSPECTGBM #TargetedTherapy #PSTV #BrainHealthForAllAges
Recent Comments